(±)-Lisofylline
This product is not available for sale in your country. Please feel free to contact the help desk if you have any questions.
Specifications
| CAS No | 6493-06-7 |
| MW | 280.3 |
| Country Availability | DK, EE, FI, IS, LT, LV, NO, SE |
| Data Sheet Link | https://www.adipogen.com/productmanagement/resource/download/type/sheet/id/6766 |
| Description | (±)-Lisofylline |
| Supplier | Adipogen Life Sciences |
| Notes | Chemical. CAS: 6493-06-7. Formula: C13H20N4O3. MW: 280.3. Synthetic. Synthetic methylxanthine metabolite of pentoxifylline. Potent anti-inflammatory agent in which only the (−) optical isomer is biologically active. Inhibits the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase (LPAAT), which has been shown to protect mice from endotoxic shock. Decreases lipid peroxidation in vitr oand in vivo. Suppresses the production of the proinflammatory cytokine IFN-gamma, inhibits IL-12-mediated STAT-4 activation, enhances glucose-stimulated beta-cell insulin secretion, reducing the onset of diabetes in a non-obese diabetic mouse model, and blocks autoimmune deterioration of pancreatic beta cells in non-obese diabetic mice. Compound can be used as analytical reference material. |
| Molecular Formula | C13H20N4O3 |
| Alias Names | 1-(5'-Hydroxyhexyl)-3,7-dimethylxanthine; LSF; BL 194; CT-1501R; 5-Hydroxy pentoxifylline |
| Purity | >99% (HPLC) |
| References | (1) G.C. Rice, et al.; PNAS 91, 3857 (1994) | (2) E. Clarke, et al.; Cancer Res. 56, 105 (1996) | (3) N. Hasegawa, et al.; Am. J. Respir. Crit. Care Med. 155, 928 (1997) | (4) S. Itani, et al.; Metabolism 50, 553 (2001) | (5) S. Itani, et al.; Diabetes 51, 2005 (2002) | (6) M. Chen, et al.; Endocrinol. 143, 2341 (2002) | (7) Z. Yang, et al.; Ann. N.Y. Acad. Sci. 1005, 409 (2003) | (8) J.S. Striffler, et al;.Metab. Clin. Exp. 53, 290 (2004) | (9) Z. Yang, et al.; Biochem. Pharmacol. 69, 1 (2005) | (10) E. Wyska; Pharmacology 85, 264 (2010) |
| Solubility | Soluble in chloroform. |
| Storage | -20°C |
| Technical Specifications | Synthetic methylxanthine metabolite of pentoxifylline. Potent anti-inflammatory agent in which only the (−) optical isomer is biologically active. Inhibits the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase (LPAAT), which has been shown to protect mice from endotoxic shock. Decreases lipid peroxidation in vitr oand in vivo. Suppresses the production of the proinflammatory cytokine IFN-gamma, inhibits IL-12-mediated STAT-4 activation, enhances glucose-stimulated beta-cell insulin secretion, reducing the onset of diabetes in a non-obese diabetic mouse model, and blocks autoimmune deterioration of pancreatic beta cells in non-obese diabetic mice. Compound can be used as analytical reference material. |
Shipping info
The delivery time for this item is approximately 5-8 business days. If other deviations occur, this will be noted on the order confirmation or communicated via email. Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.
Product insert:
Datasheet